FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1657838061> ?p ?o ?g. }

• W1657838061 abstract "Objective: Assess real-world efficacy and safety of onabotulinumtoxinA for the treatment of chronic migraine (CM), including patients with comorbid states of anxiety and/or depression.Background: Few CM treatment options are available, which are often further limited due to side effects. OnabotulinumtoxinA is approved for headache prophylaxis in CM and has demonstrated a favorable safety and efficacy profile; however, data are limited to 56 weeks. COMPEL was designed to evaluate the longer-term efficacy and safety of onabotulinumtoxinA for CM.Methods: This is a multicenter, open-label study in adult CM patients treated with 155U onabotulinumtoxinA every 12 weeks (NCT01516892). Change in frequency of headache days from baseline at 108 weeks (following 9 treatments) is the primary efficacy measure. Additional measures include headache impact test (HIT-6), migraine disability assessment questionnaire (MIDAS), generalized anxiety disorder assessment (GAD-7), and patient health questionnaire (PHQ-9). Interim data to week 24 (following 2 treatments) are summarized using descriptive statistics. The safety cohort includes all patients receiving 蠅1 onabotulinumtoxinA treatment.Results: 713 enrolled patients who received study medication were 18-73 years old, predominantly female (N=603, 85[percnt]) and Caucasian (N=579, 81[percnt]). 691 patients included in the interim analyses reported an average 22 (SD=4.8) headache days per month at baseline. By week 24, a significant reduction (-7.6 days, p<0.0001) in number of headache days was observed (mean=14, SD=7.8). Patients also demonstrated significant improvements (p<0.0001) in HIT-6 (-5 point change) and MIDAS (-36 point change) scores from baseline, with moderate improvements in GAD-7 and PHQ-9 scores. A total of 106 (15[percnt]) patients reported 蠅1 treatment-related adverse events (TRAEs); 1 considered serious (rash). Most frequently reported TRAE was neck pain (N=21, 3[percnt])Conclusions: Consistent with previously published findings, interim data from COMPEL supports the efficacy and safety of onabotulinumtoxinA for headache prophylaxis in CM, up to 24 weeks.Study Supported by: Allergan, Inc. Disclosure: Dr. Blumenfeld has received personal compensation with Allergan, Zogenix, Inc., Depomed, Inc., Forest Laboratories, and Keller Labs as a speaker, advisory board member and/or consultant. Dr. Stark has received personal compensation for activities with Allergan, Inc., Merck Sharp & Dohme Ltd., Invivo, and Pfizer Inc. Dr. Reppine has received personal compensation for activities with Allergan, Inc. as an employee. Dr. Halstead has received personal compensation for activities with Allergan, Inc. as an employee. Dr. Holdbrook has received personal compensation for activities with Allergan, Inc. as an employee. Dr. Aurora has received personal compensation for activities with Merck, Allergan, and eNeura." @default.
• W1657838061 created "2016-06-24" @default.
• W1657838061 creator A5011373273 @default.
• W1657838061 creator A5028645679 @default.
• W1657838061 creator A5039333995 @default.
• W1657838061 creator A5050252532 @default.
• W1657838061 creator A5059017023 @default.
• W1657838061 creator A5071270561 @default.
• W1657838061 date "2015-04-06" @default.
• W1657838061 modified "2023-09-24" @default.
• W1657838061 title "Efficacy and Safety of OnabotulinumtoxinA in a Long-Term, Open-Label Study for the Prophylaxis of Headaches in Adult Chronic Migraine Patients: An Interim Analysis of the COMPEL Study (P1.306)" @default.
• W1657838061 hasPublicationYear "2015" @default.
• W1657838061 type Work @default.
• W1657838061 sameAs 1657838061 @default.
• W1657838061 citedByCount "0" @default.
• W1657838061 crossrefType "journal-article" @default.
• W1657838061 hasAuthorship W1657838061A5011373273 @default.
• W1657838061 hasAuthorship W1657838061A5028645679 @default.
• W1657838061 hasAuthorship W1657838061A5039333995 @default.
• W1657838061 hasAuthorship W1657838061A5050252532 @default.
• W1657838061 hasAuthorship W1657838061A5059017023 @default.
• W1657838061 hasAuthorship W1657838061A5071270561 @default.
• W1657838061 hasConcept C118552586 @default.
• W1657838061 hasConcept C126322002 @default.
• W1657838061 hasConcept C139719470 @default.
• W1657838061 hasConcept C141071460 @default.
• W1657838061 hasConcept C162324750 @default.
• W1657838061 hasConcept C1862650 @default.
• W1657838061 hasConcept C187212893 @default.
• W1657838061 hasConcept C197934379 @default.
• W1657838061 hasConcept C203092338 @default.
• W1657838061 hasConcept C2776867660 @default.
• W1657838061 hasConcept C2778529449 @default.
• W1657838061 hasConcept C2778541695 @default.
• W1657838061 hasConcept C2780966972 @default.
• W1657838061 hasConcept C2910587157 @default.
• W1657838061 hasConcept C3019858935 @default.
• W1657838061 hasConcept C535046627 @default.
• W1657838061 hasConcept C558461103 @default.
• W1657838061 hasConcept C61943457 @default.
• W1657838061 hasConcept C71924100 @default.
• W1657838061 hasConcept C72563966 @default.
• W1657838061 hasConceptScore W1657838061C118552586 @default.
• W1657838061 hasConceptScore W1657838061C126322002 @default.
• W1657838061 hasConceptScore W1657838061C139719470 @default.
• W1657838061 hasConceptScore W1657838061C141071460 @default.
• W1657838061 hasConceptScore W1657838061C162324750 @default.
• W1657838061 hasConceptScore W1657838061C1862650 @default.
• W1657838061 hasConceptScore W1657838061C187212893 @default.
• W1657838061 hasConceptScore W1657838061C197934379 @default.
• W1657838061 hasConceptScore W1657838061C203092338 @default.
• W1657838061 hasConceptScore W1657838061C2776867660 @default.
• W1657838061 hasConceptScore W1657838061C2778529449 @default.
• W1657838061 hasConceptScore W1657838061C2778541695 @default.
• W1657838061 hasConceptScore W1657838061C2780966972 @default.
• W1657838061 hasConceptScore W1657838061C2910587157 @default.
• W1657838061 hasConceptScore W1657838061C3019858935 @default.
• W1657838061 hasConceptScore W1657838061C535046627 @default.
• W1657838061 hasConceptScore W1657838061C558461103 @default.
• W1657838061 hasConceptScore W1657838061C61943457 @default.
• W1657838061 hasConceptScore W1657838061C71924100 @default.
• W1657838061 hasConceptScore W1657838061C72563966 @default.
• W1657838061 hasOpenAccess W1657838061 @default.
• W1657838061 hasRelatedWork W1016980274 @default.
• W1657838061 hasRelatedWork W1042487492 @default.
• W1657838061 hasRelatedWork W1555860353 @default.
• W1657838061 hasRelatedWork W1987630964 @default.
• W1657838061 hasRelatedWork W2027348910 @default.
• W1657838061 hasRelatedWork W2461310150 @default.
• W1657838061 hasRelatedWork W2472696471 @default.
• W1657838061 hasRelatedWork W2562731026 @default.
• W1657838061 hasRelatedWork W2770501766 @default.
• W1657838061 hasRelatedWork W2777881032 @default.
• W1657838061 hasRelatedWork W2795807623 @default.
• W1657838061 hasRelatedWork W2809523820 @default.
• W1657838061 hasRelatedWork W2809684180 @default.
• W1657838061 hasRelatedWork W2883358571 @default.
• W1657838061 hasRelatedWork W2890443921 @default.
• W1657838061 hasRelatedWork W2899506043 @default.
• W1657838061 hasRelatedWork W2913186854 @default.
• W1657838061 hasRelatedWork W3126954968 @default.
• W1657838061 hasRelatedWork W3159959646 @default.
• W1657838061 hasRelatedWork W3202171324 @default.
• W1657838061 hasVolume "84" @default.
• W1657838061 isParatext "false" @default.
• W1657838061 isRetracted "false" @default.
• W1657838061 magId "1657838061" @default.
• W1657838061 workType "article" @default.